British Pharmacopoeia (BP) 2027 – Multi-User Licence
The BP 2027 edition supersedes the BP 2026 and becomes legally effective on 1 January 2027 with all European Pharmacopoeia texts included. Updated annually, the British Pharmacopoeia (BP) is the only comprehensive collection of authoritative official standards for UK pharmaceutical substances and medicinal products.
It includes approximately 4,000 monographs, which are legally enforced by the Human Medicines Regulations 2013. Medicinal products or active pharmaceutical ingredients sold or supplied in the UK must comply with the relevant monograph. All monographs and requirements of the European Pharmacopoeia (Ph. Eur.) are reproduced in the BP, making the BP a convenient and fully comprehensive set of standards that can be used across Europe and internationally.
Multi User License
Optimised Access for Teams: Allows multiple licensed users to access BP Online simultaneously — ideal for national or global operations.
Flexible Licensing Models:
Standard MUL: Limited number of concurrent users within one country
Global Unlimited MUL: Unlimited concurrent users across multiple countries
Academic Unlimited MUL: Unlimited access for eligible educational institutions
Cost-Effective Shared Access: Pay only for expected concurrent users, rather than per seat.
Seamless Access Management:
Invite users via licence managers
Automatic access via domain recognition
Integration with Athens/Shibboleth (academic licences)
Trusted Worldwide: Used by pharmaceutical, regulatory, academic, and healthcare organisations.
New for the BP 2027 edition
18 new BP monographs and all new texts added with Issues 12.1 to 13.1 of the Ph. Eur.
One new infrared reference spectrum has been added
to the collection
13 new BPCRS
132 amended BP texts
All texts from the Ph. Eur. up to Issue 14.1 included
as in-year online and download updates
